Emodin protects against high-fat diet-induced obesity via regulation of amp-activated protein kinase pathways in white adipose tissue

Planta Medica

Volumn 78, Issue 10, 2012, Pages 943-950

  Tzeng, Thing Fong ^a   Lu, Hung Jen ^b   Liou, Shorong Shii ^c   Chang, Chiaju ^d   Liu, I Min ^c  

^a Pao Chien Hospital   (Taiwan)

^b KAOHSIUNG VETERANS GENERAL HOSPITAL   (Taiwan)

^c TAJEN UNIVERSITY   (Taiwan)

^d CHINA MEDICAL UNIVERSITY   (Taiwan)

Author keywords

AMPK; emodin; high fat diet; lipid; white adipose tissue

Indexed keywords

ACETYL COENZYME A CARBOXYLASE; CARNITINE PALMITOYLTRANSFERASE I; EMODIN; FATTY ACID SYNTHASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; PIOGLITAZONE; STEROL REGULATORY ELEMENT BINDING PROTEIN 1;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFECT; DRUG MECHANISM; ENZYME PHOSPHORYLATION; LIPID DIET; MALE; MOUSE; NONHUMAN; OBESITY; RAT; TREATMENT OUTCOME; WHITE ADIPOSE TISSUE;

3T3-L1 CELLS; ADIPOCYTES, WHITE; ADIPOSE TISSUE, WHITE; AMP-ACTIVATED PROTEIN KINASES; ANIMALS; ANTI-OBESITY AGENTS; BLOTTING, WESTERN; BODY WEIGHT; CELL DIFFERENTIATION; DIET, ATHEROGENIC; DIET, HIGH-FAT; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; EMODIN; FEEDING BEHAVIOR; GENE EXPRESSION REGULATION, ENZYMOLOGIC; LIPID METABOLISM; MALE; MICE; OBESITY; PHOSPHORYLATION; PLANT PREPARATIONS; RATS; RATS, WISTAR; RHEUM; SEVERITY OF ILLNESS INDEX; THIAZOLIDINEDIONES; TRIGLYCERIDES;

RATTUS;

EID: 84863599060     PISSN: 00320943     EISSN: 14390221     Source Type: Journal    
DOI: 10.1055/s-0031-1298626     Document Type: Article

References (30)

1. Selassie M, Sinha AC. The epidemiology and aetiology of obesity: a global challenge. Best Pract Res Clin Anaesthesiol: 2011; 25 1 9
2. Karpe F, Dickmann JR, Fraynm KN. Fatty acids, obesity, and insulin resistance: time for a reevaluation. Diabetes: 2011; 60 2441 2449
3. Achike FI, To NH, Wang H, Kwan CY. Obesity, metabolic syndrome, adipocytes and vascular function: A holistic viewpoint. Clin Exp Pharmacol Physiol: 2011; 38 1 10
4. Greenway FL, Caruso MK. Safety of obesity drugs. Expert Opin Drug Saf: 2005; 4 1083 1095 (Pubitemid 41671605)
5. Zheng CD, Duan YQ, Gao JM, Ruan ZG. Screening for anti-lipase properties of 37 traditional Chinese medicinal herbs. J Chin Med Assoc: 2010; 7 319 324
6. Chang CH, Lin CC, Yang JJ. Anti-inflammatory effects of emodin from Ventilago leiocarpa. Am J Chin Med: 1996; 24 139 142
7. Zhou M, Xu H, Pan L, Wen J, Guo Y, Chen K. Emodin promotes atherosclerotic plaque stability in fat-fed apolipoprotein E-deficient mice. Tohoku J Exp Med: 2008; 215 261 269
8. Hei ZQ, Huang HQ, Tan HM. Emodin inhibits dietary induced atherosclerosis by antioxidation and regulation of the sphingomyelin pathway in rabbits. Chin Med J: 2006; 119 868 870
9. Xue J, Ding W, Liu Y. Anti-diabetic effects of emodin involved in the activation of PPARgamma on high-fat diet-fed and low dose of streptozotocin-induced diabetic mice. Fitoterapia: 2010; 81 173 177
10. Lage R, Diéguez C, Vidal-Puig A, López M. AMPK: a metabolic gauge regulating whole-body energy homeostasis. Trends Mol Med: 2008; 14 539 549
11. Dong H, Lu FE, Gao ZQ, Xu LJ, Wang KF, Zou X. Effects of emodin on treating murine nonalcoholic fatty liver induced by high caloric laboratory chaw. World J Gastroenterol: 2005; 11 1339 1344 (Pubitemid 40425917)
12. Rosen ED, Walkey CJ, Puigserver P, Spiegelman BM. Transcriptional regulation of adipogenesis. Genes Dev: 2000; 14 1293 1307 (Pubitemid 30397073)
13. Feldeisen SE, Tucker KL. Nutritional strategies in the prevention and treatment of metabolic syndrome. Appl Physiol Nutr Metab: 2007; 32 46 60
14. Hariri N, Thibault L. High-fat diet-induced obesity in animal models. Nutr Res Rev: 2010; 23 270 299
15. Van Heek M, Compton DS, France CF, Tedesco RP, Fawzi B, Graziano MP, Sybertz EJ, Strader CD, Davis HR Jr. Diet-induced obese mice develop peripheral, but not central, resistance to leptin. J Clin Invest: 1997; 99 385 390 (Pubitemid 27414794)
16. Zhao XY, Qiao GF, Li BX, Chai LM, Li Z, Lu YJ, Yang BF. Hypoglycaemic and hypolipidaemic effects of emodin and its effect on L-type calcium channels in dyslipidaemic-diabetic rats. Clin Exp Pharmacol Physiol: 2009; 36 29 34
17. Ding SY, Shen ZF, Chen YT, Sun SJ, Liu Q, Xie MZ. Pioglitazone can ameliorate insulin resistance in low-dose streptozotocin and high sucrose-fat diet induced obese rats. Acta Pharmacol Sin: 2005; 26 575 580 (Pubitemid 40676168)
18. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low density lipoprotein cholesterol in plasma without use of preparative ultracentrifuge. Clin Chem: 1972; 18 499 502
19. Abbott RD, Wilson PW, Kannel WB, Castelli WP. High density lipoprotein-cholesterol, total cholesterol screening and myocardial infarction. The Framingham Study. Arterosclerosis: 1988; 8 207 211
20. Shanmugasundaram KR, Visvanathan A, Dhandapani K, Srinivasan N, Rasappan P, Gilbert R, Alladi S, Kancharla S, Vasanthi N. Effect of high-fat diet on cholesterol distribution in plasma lipoproteins, cholesterol esterifying activity in leucocytes, and erythrocyte membrane components studied: importance of body weight. Am J Clin Nutr: 1986; 44 805 815 (Pubitemid 17209001)
21. Breuer HW. Hypertriglyceridemia: a review of clinical relevance and treatment options: focus on cerivastatin. Curr Med Res Opin: 2001; 17 60 73
22. Trayhurn P. Adipocyte biology. Obes Rev: 2007; 8 41 44
23. Cowherd RM, Lyle RE, McGehee REJ. Molecular regulation of adipocyte differentiation. Semin Cell Dev Biol: 1999; 10 3 10 (Pubitemid 129505533)
24. Siersbaek R, Nielsen R, Mandrup S. PPARgamma in adipocyte differentiation and metabolism-novel insights from genome-wide studies. FEBS Lett: 2010; 584 3242 3249
25. Björntorp P. Number and size of adipose tissue fat cells in relation to metabolism in human obesity. Metabolism: 1971; 20 703 713
26. Franssen R, Monajemi H, Stroes ES, Kastelein JJ. Obesity and dyslipidemia. Med Clin North Am: 2011; 95 893 902
27. Longo N, Amat di San Filippo C, Pasquali M. Disorders of carnitine transport and the carnitine cycle. Am J Med Genet C Semin Med Genet: 2006; 142?C 77 85
28. Hagen RM, Rodriguez-Cuenca S, Vidal-Puig A. An allostatic control of membrane lipid composition by SREBP1. FEBS Lett: 2010; 584 2689 2698
29. Li Y, Xu S, Mihaylova MM, Zheng B, Hou X, Jiang B, Park O, Luo Z, Lefai E, Shyy JY, Gao B, Wierzbicki M, Verbeuren TJ, Shaw RJ, Cohen RA, Zang M. AMPK phosphorylates and inhibits SREBP activity to attenuate hepatic steatosis and atherosclerosis in diet-induced insulin-resistant mice. Cell Metab: 2011; 13 376 388
30. Zhou G, Myers R, Li Y, Chen Y, Shen X, Fenyk-Melody J, Wu M, Ventre J, Doebber T, Fujii N, Musi N, Hirshman MF, Goodyear LJ, Moller DE. Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest: 2001; 108 1167 1174 (Pubitemid 32995375)